BASFs Nutrition & Health Division to Focus on Growth and Increased Competitiveness
BASF is implementing a series of measures within the Nutrition & Health division to strengthen the competitiveness of its Performance Products segment. The Nutrition & Health division bundles BASF’s products and solutions for human and animal nutrition, the flavor and fragrance industry, as well as the pharmaceutical industry.
BASF is adjusting its product portfolio to better meet changing consumer needs and regional demands. In Asia, BASF is building a citral plant with its partner Petronas to meet the growing demand of customers in the flavor and fragrance industry in the region. The first plants of the complex are expected to come on stream in 2016. At the same time, BASF will focus its production in the growing market of omega-3 fatty acids on the attractive market segment for highly concentrated omega-3 fatty acids and plans to sell the Norwegian Brattvåg site. BASF produces low concentrated omega-3 fatty acids at this site.
Marketing, sales and administration will be better adjusted to regional market dynamics. A global team responsible for marketing and innovation will in future support the development of customer-oriented products and solutions as well as faster market launches of new products. BASF aims to accelerate the innovation cycle of products for its customers through strategic partnerships.
Due to the planned measures about 260 positions in production, marketing and administration will be reduced globally by end of 2015. Consultations with the responsible employee representatives will be conducted.
“We aim to strengthen our position in the growing nutrition and health market. Through these measures we will adapt our business to better meet market and customer needs. At the same time, we will improve our profitability,” said Saori Dubourg, President of BASF’s Nutrition & Health division.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance